Aegerion Pharmaceuticals, Inc.
DelistedCIK 1338042fmd_1GQPNJY25TSYWB2YPD89F1A3DWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Sep 30, 2016, 30 periods
| Line item | FY2006 | FY2007 | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | – | – | – | – | – | – | – | 5 | 14 | 52 |
| Research and development | – | – | – | 7 | 8 | 24 | 25 | 30 | 38 | 45 |
| Selling, general and administrative | – | – | – | – | 6 | 14 | 34 | 76 | 133 | 188 |
| Total operating expenses | – | – | – | 10 | 14 | 39 | 61 | 106 | 171 | 233 |
| Operating income | – | – | – | (10) | (14) | (39) | (61) | (62) | (27) | (45) |
| Interest expense | – | – | – | 2 | 2 | 1 | 1 | 0 | 10 | 28 |
| Interest and investment income | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Other non-operating income (expense) | – | – | – | – | 0 | 1 | (1) | (0) | (2) | 1 |
| Income before taxes | – | – | – | (12) | (16) | (39) | (62) | (63) | (38) | (72) |
| Income tax expense | – | – | – | – | (2) | – | – | 0 | 1 | 2 |
| Net income from continuing operations | – | – | – | – | (14) | – | – | (63) | (39) | (73) |
| Net income | (6) | (20) | (25) | (12) | (14) | (39) | (62) | (63) | (39) | (73) |
| Net income to common shareholders | – | – | – | (15) | (23) | (39) | (62) | – | – | – |